Cargando…
Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
Background and Purpose Accurate and rapid assessment of coagulation status is necessary to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially available point-of-care (POC) assays are not suited for coagulation testing in patients treated with direct oral anticoag...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180376/ https://www.ncbi.nlm.nih.gov/pubmed/33469905 http://dx.doi.org/10.1055/s-0040-1721775 |
_version_ | 1783703990091907072 |
---|---|
author | Härtig, Florian Birschmann, Ingvild Peter, Andreas Ebner, Matthias Spencer, Charlotte Gramlich, Michael Richter, Hardy Kuhn, Joachim Lehmann, Rainer Blumenstock, Gunnar Zuern, Christine S. Ziemann, Ulf Poli, Sven |
author_facet | Härtig, Florian Birschmann, Ingvild Peter, Andreas Ebner, Matthias Spencer, Charlotte Gramlich, Michael Richter, Hardy Kuhn, Joachim Lehmann, Rainer Blumenstock, Gunnar Zuern, Christine S. Ziemann, Ulf Poli, Sven |
author_sort | Härtig, Florian |
collection | PubMed |
description | Background and Purpose Accurate and rapid assessment of coagulation status is necessary to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially available point-of-care (POC) assays are not suited for coagulation testing in patients treated with direct oral anticoagulants (DOACs). We aimed to evaluate the direct thrombin monitoring (DTM) test card by Helena Laboratories (Texas, United States) for anti-IIa-specific POC coagulation testing, hypothesizing that its POC-ecarin clotting time (POC-ECT) accurately reflects dabigatran plasma concentrations. Methods A prospective single-center diagnostic study (ClinicalTrials.gov-identifier: NCT02825394) was conducted enrolling patients receiving a first dose of dabigatran and patients already on dabigatran treatment. Blood samples were collected before drug intake and 0.5, 1, 2, 8, and 12 hours after intake. POC-ECT was performed using whole blood (WB), citrated blood (CB), and citrated plasma (CP). Dabigatran plasma concentrations were determined by mass spectrometry. Results In total, 240 blood samples from 40 patients contained 0 to 275 ng/mL of dabigatran. POC-ECT with WB/CB/CP ranged from 20 to 186/184/316 seconds. Pearson's correlation coefficient showed a strong correlation between dabigatran concentrations and POC-ECT with WB/CB/CP ( R (2) = 0.78/0.90/0.92). Dabigatran concentrations >30 and >50 ng/mL (thresholds for thrombolysis, surgery, and reversal therapy according to clinical guidelines) were detected by POC-ECT with WB/CB/CP (>36/35/45 and >43/45/59 seconds) with 95/97/97 and 96/98/97% sensitivity, and 81/87/94 and 74/60/91% specificity. Conclusion This first study evaluating DOAC-specific POC coagulation testing revealed an excellent correlation of POC-ECT with actual dabigatran concentrations. Detecting clinically relevant dabigatran levels with high sensitivity/specificity, the DTM assay represents a suitable diagnostic tool in acute stroke, hemorrhage, and urgent surgery. |
format | Online Article Text |
id | pubmed-8180376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-81803762021-06-08 Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran Härtig, Florian Birschmann, Ingvild Peter, Andreas Ebner, Matthias Spencer, Charlotte Gramlich, Michael Richter, Hardy Kuhn, Joachim Lehmann, Rainer Blumenstock, Gunnar Zuern, Christine S. Ziemann, Ulf Poli, Sven Thromb Haemost Background and Purpose Accurate and rapid assessment of coagulation status is necessary to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially available point-of-care (POC) assays are not suited for coagulation testing in patients treated with direct oral anticoagulants (DOACs). We aimed to evaluate the direct thrombin monitoring (DTM) test card by Helena Laboratories (Texas, United States) for anti-IIa-specific POC coagulation testing, hypothesizing that its POC-ecarin clotting time (POC-ECT) accurately reflects dabigatran plasma concentrations. Methods A prospective single-center diagnostic study (ClinicalTrials.gov-identifier: NCT02825394) was conducted enrolling patients receiving a first dose of dabigatran and patients already on dabigatran treatment. Blood samples were collected before drug intake and 0.5, 1, 2, 8, and 12 hours after intake. POC-ECT was performed using whole blood (WB), citrated blood (CB), and citrated plasma (CP). Dabigatran plasma concentrations were determined by mass spectrometry. Results In total, 240 blood samples from 40 patients contained 0 to 275 ng/mL of dabigatran. POC-ECT with WB/CB/CP ranged from 20 to 186/184/316 seconds. Pearson's correlation coefficient showed a strong correlation between dabigatran concentrations and POC-ECT with WB/CB/CP ( R (2) = 0.78/0.90/0.92). Dabigatran concentrations >30 and >50 ng/mL (thresholds for thrombolysis, surgery, and reversal therapy according to clinical guidelines) were detected by POC-ECT with WB/CB/CP (>36/35/45 and >43/45/59 seconds) with 95/97/97 and 96/98/97% sensitivity, and 81/87/94 and 74/60/91% specificity. Conclusion This first study evaluating DOAC-specific POC coagulation testing revealed an excellent correlation of POC-ECT with actual dabigatran concentrations. Detecting clinically relevant dabigatran levels with high sensitivity/specificity, the DTM assay represents a suitable diagnostic tool in acute stroke, hemorrhage, and urgent surgery. Georg Thieme Verlag KG 2021-06 2021-01-14 /pmc/articles/PMC8180376/ /pubmed/33469905 http://dx.doi.org/10.1055/s-0040-1721775 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Härtig, Florian Birschmann, Ingvild Peter, Andreas Ebner, Matthias Spencer, Charlotte Gramlich, Michael Richter, Hardy Kuhn, Joachim Lehmann, Rainer Blumenstock, Gunnar Zuern, Christine S. Ziemann, Ulf Poli, Sven Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran |
title | Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran |
title_full | Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran |
title_fullStr | Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran |
title_full_unstemmed | Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran |
title_short | Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran |
title_sort | specific point-of-care testing of coagulation in patients treated with dabigatran |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180376/ https://www.ncbi.nlm.nih.gov/pubmed/33469905 http://dx.doi.org/10.1055/s-0040-1721775 |
work_keys_str_mv | AT hartigflorian specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT birschmanningvild specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT peterandreas specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT ebnermatthias specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT spencercharlotte specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT gramlichmichael specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT richterhardy specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT kuhnjoachim specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT lehmannrainer specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT blumenstockgunnar specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT zuernchristines specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT ziemannulf specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran AT polisven specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran |